Skip to contentS
Spyre Therapeutics, Inc.
S
SYRESpyre Therapeutics, Inc. Q1 2019 · 10-Q
Revenue$0.00$0.00−100.0% vs Q1 2018 Net Income-$17.17M-$17.17MN/M vs Q1 2018 EPS Diluted-$0.59-$0.59N/M vs Q1 2018 Operating Income-$17,657,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
Free Cash Flowderived-$15,925,000N/M ended Mar 31, 2019 · filed May 7, 2019 · 37 d after period end